AKRO
Price
$47.74
Change
+$1.52 (+3.29%)
Updated
Sep 26 closing price
Capitalization
3.82B
46 days until earnings call
IDYA
Price
$26.83
Change
+$1.14 (+4.44%)
Updated
Sep 26 closing price
Capitalization
2.35B
45 days until earnings call
Interact to see
Advertisement

AKRO vs IDYA

Header iconAKRO vs IDYA Comparison
Open Charts AKRO vs IDYABanner chart's image
Akero Therapeutics
Price$47.74
Change+$1.52 (+3.29%)
Volume$732.1K
Capitalization3.82B
IDEAYA Biosciences
Price$26.83
Change+$1.14 (+4.44%)
Volume$1.85M
Capitalization2.35B
AKRO vs IDYA Comparison Chart in %
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. IDYA commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Hold and IDYA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (AKRO: $47.74 vs. IDYA: $26.83)
Brand notoriety: AKRO and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 68% vs. IDYA: 153%
Market capitalization -- AKRO: $3.82B vs. IDYA: $2.35B
AKRO [@Biotechnology] is valued at $3.82B. IDYA’s [@Biotechnology] market capitalization is $2.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 1 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • AKRO’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, both AKRO and IDYA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 5 TA indicator(s) are bullish while IDYA’s TA Score has 5 bullish TA indicator(s).

  • AKRO’s TA Score: 5 bullish, 4 bearish.
  • IDYA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both AKRO and IDYA are a good buy in the short-term.

Price Growth

AKRO (@Biotechnology) experienced а +5.57% price change this week, while IDYA (@Biotechnology) price change was +4.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

AKRO is expected to report earnings on Nov 12, 2025.

IDYA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKRO($3.82B) has a higher market cap than IDYA($2.35B). AKRO YTD gains are higher at: 71.603 vs. IDYA (4.397). AKRO has higher annual earnings (EBITDA): -279.17M vs. IDYA (-380.2M). AKRO has more cash in the bank: 742M vs. IDYA (670M). IDYA has less debt than AKRO: IDYA (26.6M) vs AKRO (37.2M). IDYA has higher revenues than AKRO: IDYA (7M) vs AKRO (0).
AKROIDYAAKRO / IDYA
Capitalization3.82B2.35B162%
EBITDA-279.17M-380.2M73%
Gain YTD71.6034.3971,628%
P/E RatioN/AN/A-
Revenue07M-
Total Cash742M670M111%
Total Debt37.2M26.6M140%
FUNDAMENTALS RATINGS
AKRO vs IDYA: Fundamental Ratings
AKRO
IDYA
OUTLOOK RATING
1..100
6380
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
61
Fair valued
PROFIT vs RISK RATING
1..100
7469
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5346
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKRO's Valuation (32) in the null industry is in the same range as IDYA (61). This means that AKRO’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (69) in the null industry is in the same range as AKRO (74). This means that IDYA’s stock grew similarly to AKRO’s over the last 12 months.

IDYA's SMR Rating (97) in the null industry is in the same range as AKRO (97). This means that IDYA’s stock grew similarly to AKRO’s over the last 12 months.

IDYA's Price Growth Rating (46) in the null industry is in the same range as AKRO (53). This means that IDYA’s stock grew similarly to AKRO’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as AKRO (100). This means that IDYA’s stock grew similarly to AKRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKROIDYA
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 3 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 3 days ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 13 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 3 days ago
70%
Aroon
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BPLSX14.850.14
+0.95%
Boston Partners Long/Short Equity Instl
JDIAX55.230.30
+0.55%
Janus Henderson Overseas A
NRICX22.490.08
+0.36%
Nuveen Real Asset Income C
VVJFX76.46N/A
N/A
Voya Multi-Manager Intl Sm Cp R6
RNWEX93.30-0.35
-0.37%
American Funds New World R4

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+3.29%
ETNB - AKRO
53%
Loosely correlated
N/A
SLS - AKRO
42%
Loosely correlated
+1.24%
VTYX - AKRO
38%
Loosely correlated
+10.78%
MDGL - AKRO
37%
Loosely correlated
+0.29%
IDYA - AKRO
35%
Loosely correlated
+4.44%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+4.44%
IMNM - IDYA
60%
Loosely correlated
+14.13%
SYRE - IDYA
58%
Loosely correlated
+4.04%
CGON - IDYA
58%
Loosely correlated
+2.91%
NRIX - IDYA
57%
Loosely correlated
+7.20%
NUVL - IDYA
57%
Loosely correlated
+4.99%
More